Drug intelligence / Profile preview

temozolomide + vorinostat

Development stage: Unknown
Lead developer: Aston University
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of temozolomide, an alkylating agent that damages DNA in cancer cells, and vorinostat, a histone deacetylase (HDAC) inhibitor with radiosensitizing properties. This combination has been studied primarily for the treatment of glioblastoma and other high-grade gliomas, often administered concurrently with radiation therapy.

Targets

HDAC (HDAC family)DNA

Beyond the preview

Go deeper on temozolomide + vorinostat.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on temozolomide + vorinostat.

Explore the full profile